• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories

    8/28/23 10:37:08 AM ET
    $AMGN
    $BV
    $GDC
    $HE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $AMGN alert in real time by email

    Reuters

    Walmart Settles Lawsuit Regarding Allegations Of Light-Bulb Patent Infringement

    • Walmart Inc (NYSE:WMT) has reportedly resolved the University of California's light-bulb patent lawsuit.
    • The university accused the retail behemoth of infringing its patents associated with "filament" LED light bulbs (invented at the Santa Barbara-based school system).
    • The federal judge in Los Angeles would dismiss the case with prejudice, which means it cannot be refiled.

    Renault Eyes Spring 2024 IPO For EV Unit Ampere

    • Renault SA (OTC:RNLSY) (OTC:RNSDF) is reportedly expecting to list its electric vehicle business unit, Ampere, on the stock market in the spring of 2024.
    • Renault Chief Executive Officer Luca de Meo said the automaker was targeting November 1 of this year for Ampere to be separated from the rest of the company.
    • "So we separate, and then we see if we have the right conditions to enter the market," said Luca de Meo.

    UBS-Owned Credit Suisse Piles Up Loss of Over $4B In Q2

    • Swiss investment bank Credit Suisse, currently a subsidiary of UBS Inc (NYSE:UBS), reportedly posted a loss of $4 billion for the second quarter, in line with the forecast issued in April.
    • Credit Suisse's second-quarter loss amounted to 3.5 billion Swiss francs.
    • Credit Suisse had previously forecast a significant pre-tax loss for the second quarter and for all of 2023, given its move to exit from non-core businesses and restructuring and financing costs.

     

    Wall Street Journal

    Purdue Pharma's Trust Strategy: Supreme Court Reviews Restructuring Amidst Opioid Crisis

    • The Supreme Court is set to examine Purdue Pharma's proposed restructuring, the opioid company that sought bankruptcy in 2019. This move may change a four-decade method for managing vast legal liabilities from large-scale lawsuits.
    • The tactic dates back to Johns Manville, a prominent asbestos firm that declared bankruptcy in 1982 due to myriad lawsuits. Despite bankruptcy laws permitting restructuring of present claims, many claimants wouldn't fall ill until years post-bankruptcy. 

    FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal

    • The Federal Trade Commission decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc (NASDAQ:AMGN), concerning its proposed acquisition of Horizon Therapeutics PLC (NASDAQ:HZNP) valued at $27.8 billion.
    • The move presents a window of opportunity to contemplate a potential settlement, which might allow the deal to move forward under specific conditions.
    • In a document submitted to the court last week, the FTC revealed its intention to suspend the challenge it had initiated internally.

     

    Bloomberg

    A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications

    • The U.S. government is set to announce a list of 10 drugs this Friday, September 1, as part of President Joe Biden's Inflation Reduction Act, for which it will actively negotiate prices. 
    • Expected on this list are Johnson & Johnson's (NYSE:JNJ) blood thinner Xarelto and Eli Lilly And Co's (NYSE:LLY) diabetes drug Jardiance.
    • This unprecedented negotiating ability shifts from the status quo, where pharmaceutical companies have primarily dictated prices. 

    China's Strategic Financial Overhaul Targets Stock Market Revival

    • In a strategic move to reinvigorate its stock market, China has unveiled a series of financial measures, including a significant cut in the stamp duty on stock trades and a slowdown in introducing initial public offerings (IPOs).
    • Beginning August 28, the stamp duty on stock trades will experience a reduction, moving from 0.1% to 0.05%. This marks the first such adjustment since 2008. The Ministry of Finance highlighted this initiative as a step to "energize capital markets and enhance investor trust.

    To Boost AI Efforts, SoftBank Plans Silicon Valley Tour For Indian Entrepreneurs

    • Japanese multinational investment holding company SoftBank Group Corp (OTC:SFTBY) (OTC:SFTBF) is taking a select group of founders from its Indian startups to Silicon Valley for a specialized AI tour in September.
    • This initiative underscores SoftBank's ongoing commitment to AI integration across its portfolio entities.

    Databricks in Talks with T. Rowe Price for $43B Valuation, Eyes Expansion

    • Software maker Databricks Inc. is discussing a new funding round with T. Rowe Price Group Inc (NASDAQ: TROW) to value the company at $43 billion.
    • The company bagged a valuation of $38 billion two years ago in funding led by Counterpoint Global.
    • Databricks provides tools for data, analytics, and artificial intelligence.

     

    Benzinga

    Tesla China Rival XPeng Taps Ride-Hailing Firm DiDi to Boost Smart EV Adoption

    • Chinese smart electric vehicle firm XPeng Inc (NYSE: XPEV) tapped domestic ride-hailing firm DiDi Global Inc (OTC: DIDIY)
    •  to drive the adoption of Smart EVs and technologies.
    • XPeng plans to launch an all-new EV brand in 2024, which it is developing under the project name "MONA." 

    Hawaiian Electric's Shares Gain After An Update On Cause Of Lahaina Fires

    • Hawaiian Electric Industries Inc (NYSE: HE) shares are gaining after the company released an in-depth response to the lawsuit recently filed by the County of Maui surrounding the tragic fires on August 8.
    • Hawaiian Electric's records confirm that no electricity flowed in its power lines near Lahaina Intermediate School when the fire ignited.
    • Videos taken by local residents depict power lines falling in strong winds earlier that morning, leading to the smaller fire.

    Chinese Carmaker BYD Buys US Firm Jabil's Mobility Business For $2.2B

    • Jabil Inc (NYSE: JBL) reached a preliminary deal with Chinese EV maker BYD Co Ltd (OTC: BYDDF) (OTC: BYDDY) BYD Electronic (International) Company Limited for the sale of its Mobility business in a potential transaction worth $2.2 billion.
    • Jabil Circuit, which manufactures printed circuit boards, established a unit this month that absorbed its product-manufacturing businesses in Chengdu and Wuxi, which will now become a part of the Chinese group.

    Hit By Opioid Lawsuits Mallinckrodt Files For Second Bankruptcy In Just Three Years

    • Mallinckrodt Plc (NYSE: MNK) has taken the next steps to implement the comprehensive financial restructuring plan.
    • The company and some of its subsidiaries have filed for a second bankruptcy in three years in the U.S., with the newest restructuring plan set to reduce its debt by about $1.9 billion.
    • The company expects to complete the court-supervised process in the fourth quarter of 2023.

    German Pharma Firm Bayer's Investigational Cell Therapy Hits Main Goal In Early Parkinson's Study

    • Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics announced detailed data from the Phase 1 trial for bemdaneprocel (BRT-DA01). Topline results were released in June.
    • The study met the primary objective of demonstrating safety and tolerability in all 12 participants in the study's low and high-dose cohorts, with no serious adverse events (SAEs) reported related to bemdaneprocel through one year. 

    Riding The TikTok Wave: GD Culture Unveils Live-Streaming E-Commerce Business And Stock Soars

    • GD Culture Group Ltd (NASDAQ: GDC) shares are skyrocketing after it announced the launch of live-streaming e-commerce business on TikTok, a popular social media platform.
    • GD Culture is a holding company currently conducting business through Shanghai Highlight Media Co Ltd. and AI Catalysis Corp (AI Catalysis). Highlight Media, founded in 2016, is an integrated marketing service agency focusing on serving businesses in China.

    BrightView Hits Refresh: New CEO And Half A Billion Dollar Investment To Slash Debt And Fuel Acquisitions

    • BrightView Holdings Inc (NYSE: BV) disclosed the new Chief Executive Officer (CEO) appointment and attained a $500 million strategic investment.
    • The company appointed Dale A. Asplund as the President and Chief Executive Officer, effective October 1, 2023. The company also appointed Asplund to the Board of directors.

    Beaten Down Chinese E-Commerce Firm Baozun Clocks Mixed Q2 Earnings

    • Chinese e-commerce solutions provider Baozun Inc (NASDAQ: BZUN) reported a second-quarter FY23 revenue growth of 9.3% year-on-year to RMB2.32 billion ($319.97 million), missing the consensus of $345.95 million.
    • Non-GAAP EPS loss per ADS was $(0.01) vs. the consensus loss of $(0.03).
    • Baozun's stock has lost 36% year-to-date.
    Get the next $AMGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $BV
    $GDC
    $HE

    CompanyDatePrice TargetRatingAnalyst
    XPeng Inc.
    $XPEV
    3/23/2026$19.00Outperform → Neutral
    Macquarie
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Jabil Inc.
    $JBL
    3/12/2026$275.00Outperform
    Robert W. Baird
    Amgen Inc.
    $AMGN
    3/10/2026$350.00Hold
    Jefferies
    Walmart Inc.
    $WMT
    3/5/2026Buy → Hold
    Erste Group
    Walmart Inc.
    $WMT
    2/27/2026$150.00Buy
    BofA Securities
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    More analyst ratings

    $AMGN
    $BV
    $GDC
    $HE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wang Fengying

    4 - XPENG INC. (0001810997) (Issuer)

    4/3/26 7:20:07 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    SEC Form 3 filed by new insider Ito Paul K

    3 - HAWAIIAN ELECTRIC INDUSTRIES INC (0000354707) (Issuer)

    4/2/26 9:43:43 PM ET
    $HE
    Electric Utilities: Central
    Utilities

    SEC Form 4 filed by Walton Steuart L

    4 - Walmart Inc. (0000104169) (Issuer)

    4/2/26 6:10:09 PM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    $AMGN
    $BV
    $GDC
    $HE
    SEC Filings

    View All

    GD Culture Group Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - GD Culture Group Ltd (0001641398) (Filer)

    4/3/26 4:00:07 PM ET
    $GDC
    Steel/Iron Ore
    Industrials

    SEC Form 6-K filed by XPeng Inc.

    6-K - XPENG INC. (0001810997) (Filer)

    4/1/26 9:45:46 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by UBS Group AG Registered

    6-K - UBS Group AG (0001610520) (Filer)

    3/31/26 9:07:23 AM ET
    $UBS
    Major Banks
    Finance

    $AMGN
    $BV
    $GDC
    $HE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cornog William L bought $67,300 worth of shares (5,000 units at $13.46) (SEC Form 4)

    4 - BrightView Holdings, Inc. (0001734713) (Issuer)

    2/9/26 4:30:07 PM ET
    $BV
    Real Estate

    Director Cornog William L bought $128,400 worth of shares (10,000 units at $12.84) (SEC Form 4)

    4 - BrightView Holdings, Inc. (0001734713) (Issuer)

    12/3/25 5:00:18 PM ET
    $BV
    Real Estate

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMGN
    $BV
    $GDC
    $HE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $BV
    $GDC
    $HE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    XPeng downgraded by Macquarie with a new price target

    Macquarie downgraded XPeng from Outperform to Neutral and set a new price target of $19.00

    3/23/26 8:28:29 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Jabil with a new price target

    Robert W. Baird initiated coverage of Jabil with a rating of Outperform and set a new price target of $275.00

    3/12/26 8:53:39 AM ET
    $JBL
    Electrical Products
    Technology

    $AMGN
    $BV
    $GDC
    $HE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEW T. ROWE PRICE PODCAST EPISODE EXAMINES THE FUTURE OF AI AND HUMAN ADVANTAGE

    A conversation on AI, curiosity, and the skills that endure BALTIMORE, April 2, 2026 /PRNewswire/ -- T. Rowe Price, a global investment management firm and leader in retirement, announces a new episode of "The Angle from T. Rowe Price," its investment-themed podcast focused on the ideas and events influencing financial markets. In the episode, "Humans vs. Machines: David Rowan on Curiosity, Creativity, and the Future of AI," Justin Thomson, head of the T. Rowe Price Investment Institute, sits down with David Rowan, technology journalist, investor, and founding editor-in-chief of

    4/2/26 9:30:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

    Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-payINDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo

    4/1/26 11:30:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

    - Collaboration with Amgen to explore the clinical potential of Zai Lab's DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA® - Amgen to sponsor and lead global Phase 1b study; Zai Lab to retain full ownership of zocilurtatug pelitecan Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-st

    4/1/26 7:30:00 AM ET
    $AMGN
    $ZLAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AMGN
    $BV
    $GDC
    $HE
    Leadership Updates

    Live Leadership Updates

    View All

    Dycom Industries, Inc. Appoints Raejeanne Skillern to Board of Directors

    WEST PALM BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE:DY) today announced the appointment of Raejeanne Skillern to its Board of Directors, effective March 24, 2026. Ms. Skillern is a highly regarded technology executive with over 30 years of leadership experience spanning hyperscale cloud, data center infrastructure, communications and artificial intelligence. She has a proven track record of leading multi-billion-dollar business units at global organizations including Amazon Web Services (AWS), Intel and Flex. "We are pleased to welcome Raejeanne to the Dycom Board of Directors," said Richard K. Sykes, Dycom's Independent Chairman of the Board. "Her de

    3/24/26 4:30:00 PM ET
    $DY
    $JBL
    Water Sewer Pipeline Comm & Power Line Construction
    Industrials
    Electrical Products
    Technology

    Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors

    BALTIMORE, March 20, 2026 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company developing advanced implantable and AI-enabled solutions for neurological health including the ClearFit AI™, the first Acoustic Brain Interface (ABI)™, today announced the appointment of Robert W. Sharps, Chief Executive Officer and President of T. Rowe Price Group, Inc. (NASDAQ:TROW), to its Board of Directors. Sharps brings three decades of leadership experience in global asset management, capital markets, corporate governance, and strategic growth. As CEO and the Chairman of the Board of T. Rowe Price, he oversees one of the world's leading investment firms, managing more than $1.5 trilli

    3/20/26 10:48:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    Walmart Names Erin Nealy Cox as Chief Legal Officer

    Cox to lead Global Governance team and assume role as Corporate Secretary Walmart Inc. (NASDAQ:WMT) announced today that Erin Nealy Cox has been named Walmart's next Executive Vice President of Global Governance, Chief Legal Officer (CLO), and Corporate Secretary. Cox will assume responsibilities on April 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312066547/en/Erin Nealy Cox, Walmart's next Executive Vice President of Global Governance, Chief Legal Officer (CLO), and Corporate Secretary. "To lead Global Governance for a company of our scale and complexity, you need a leader who has thrived in the most demandin

    3/12/26 4:00:00 PM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    $AMGN
    $BV
    $GDC
    $HE
    Financials

    Live finance-specific insights

    View All

    REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

    Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary PreventionVESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C AchievedTHOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes. The findings wer

    3/28/26 4:45:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    XPENG Reports Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    The Company achieved a positive net profit of RMB0.38 billion in the fourth quarter of 2025, recorded a positive net profit for a single quarter for the first time.Cash position[i] was RMB47.66 billion (US$6.81 billion) as of December 31, 2025Quarterly total revenues were RMB22.25 billion, a 38.2% increase year-over-yearQuarterly gross margin was 21.3%, an increase of 6.9 percentage points over the same period of 2024Quarterly vehicle margin was 13.0%, an increase of 3.0 percentage points over the same period of 2024Full year vehicle deliveries reached 429,445, a 125.9% increase year-over-yearFull year revenues reached RMB76.72 billion, an 87.7% increase year-over-yearFull year gross margin

    3/20/26 5:00:00 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    Jabil Posts Second Quarter Results

    Raises Fiscal 2026 Outlook Today, Jabil Inc. (NYSE:JBL), reported preliminary, unaudited financial results for its second quarter of fiscal year 2026. Second Quarter of Fiscal Year 2026 Highlights: Net revenue: $8.3 billion U.S. GAAP operating income: $374 million U.S. GAAP diluted earnings per share: $2.08 Core operating income (Non-GAAP): $436 million Core diluted earnings per share (Non-GAAP): $2.69 "Jabil delivered a very strong second quarter, with results ahead of our expectations across revenue, core operating margin, and core EPS," said CEO Mike Dastoor. "Our better-than-expected performance in the quarter was broad-based, reflecting the strength of our diversi

    3/18/26 7:30:00 AM ET
    $JBL
    Electrical Products
    Technology

    $AMGN
    $BV
    $GDC
    $HE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BrightView Holdings Inc.

    SC 13G - BrightView Holdings, Inc. (0001734713) (Subject)

    11/14/24 1:28:33 PM ET
    $BV
    Real Estate

    Amendment: SEC Form SC 13G/A filed by BrightView Holdings Inc.

    SC 13G/A - BrightView Holdings, Inc. (0001734713) (Subject)

    11/13/24 7:10:55 PM ET
    $BV
    Real Estate

    Amendment: SEC Form SC 13G/A filed by XPeng Inc.

    SC 13G/A - XPENG INC. (0001810997) (Subject)

    11/13/24 7:41:27 AM ET
    $XPEV
    Auto Manufacturing
    Industrials